Mandelcorn ED, Al‐Falah M, Di Zhao L, et al. - In this prospective randomized clinical trial, researchers compared the effectiveness of topical nepafenac 0.1% vs intravitreal triamcinolone acetonide (IVTA) at the conclusion of vitrectomy surgery vs no adjuvant therapy in improving macular morphology post‐operatively in patients undergoing vitrectomy for epiretinal membrane (ERM), as measured by optical coherence tomography imaging and best‐corrected visual acuity. Eighty patients scheduled for vitrectomy surgery for idiopathic ERM were randomly assigned to receive IVTA (4 mg/0.1 cc) at the end of the surgery, topical nepafenac sodium 0.1% TID for 1-month postoperation or no adjuvant treatment. According to the findings of the study, there was no benefit to using topical nepafenac or IVTA for post-vitrectomy ERM surgery.